Texas Permanent School Fund Corp Sells 5,819 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Texas Permanent School Fund Corp lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 7,294 shares of the biopharmaceutical company’s stock after selling 5,819 shares during the period. Texas Permanent School Fund Corp’s holdings in Regeneron Pharmaceuticals were worth $3,829,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Activest Wealth Management increased its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Finally, Berbice Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $748.71 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a market cap of $78.69 billion, a price-to-earnings ratio of 17.93, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37. The business has a 50-day simple moving average of $678.34 and a two-hundred day simple moving average of $597.71. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $790.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the business posted $12.46 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Analysts Set New Price Targets

A number of research analysts have issued reports on REGN shares. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Sanford C. Bernstein upped their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Finally, Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $779.45.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.